Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to... Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Mehr anzeigen
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company...
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3...
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.61 | -31.3840155945 | 5.13 | 5.13 | 3.49 | 759795 | 3.95930187 | CS |
| 4 | -1.1524 | -24.6639842479 | 4.6724 | 6.14 | 3.49 | 730340 | 4.9291947 | CS |
| 12 | -1.78 | -33.5849056604 | 5.3 | 6.37 | 3.49 | 590912 | 5.05278634 | CS |
| 26 | -1.86 | -34.5724907063 | 5.38 | 6.78 | 3.49 | 609934 | 5.09165433 | CS |
| 52 | -1.28 | -26.6666666667 | 4.8 | 8.9 | 3.49 | 626485 | 5.71973042 | CS |
| 156 | -17.8434 | -83.5232219591 | 21.3634 | 24.005 | 3.49 | 618945 | 8.64434946 | CS |
| 260 | -12.47 | -77.9862414009 | 15.99 | 45 | 3.49 | 677382 | 15.02537563 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
